Literature DB >> 7573013

Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus.

I E Coremans1, P E Spronk, H Bootsma, M R Daha, E A van der Voort, L Kater, F C Breedveld, C G Kallenberg.   

Abstract

The presence of elevated plasma levels of autoantibodies against C1q, a subcomponent of the first component of complement in sera of patients with systemic lupus erythematosus (SLE) has been found to be associated with renal involvement. The purpose of this study was to determine whether increases in anti-C1q antibodies (anti-C1q) precede renal involvement in SLE. Forty-three SLE patients were studied longitudinally to determine the relationship between manifestations of the disease and levels of anti-C1q as well as to identify antibodies against double-stranded DNA (anti-dsDNA). Increased levels of anti-C1q were detected in all 14 of the patients who developed proliferative lupus nephritis out of 17 patients with renal relapses, which was significantly more frequent (P < 0.005) than in patients with nonrenal relapses (six of 16 patients) or with inactive disease (two of 10 patients). Increased anti-dsDNA levels were observed in 14 of 17 patients with renal relapses compared with 15 of 16 patients with nonrenal relapses and five of 10 patients with inactive disease. Significant increases in anti-C1q levels prior to the relapse occurred in 10 of 14 patients who developed proliferative nephritis and in three of 16 patients with nonrenal relapses. Significant increases in anti-dsDNA levels occurred in 11 patients of the former group and in nine patients of the latter group. No significant increases in anti-C1q or anti-dsDNA levels were observed in the patients with inactive disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573013     DOI: 10.1016/0272-6386(95)90595-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  37 in total

Review 1.  Modern complement analysis.

Authors:  Michael Kirschfink; Tom E Mollnes
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

Review 2.  Autoantibodies against C1q: view on clinical relevance and pathogenic role.

Authors:  C E Siegert; M D Kazatchkine; A Sjöholm; R Würzner; M Loos; M R Daha
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

3.  T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis.

Authors:  Robert A Cohen; George Bayliss; Jose C Crispin; Gwen F Kane-Wanger; Christine A Van Beek; Vasileios C Kyttaris; Ingrid Avalos; C Yung Yu; George C Tsokos; Isaac E Stillman
Journal:  Clin Immunol       Date:  2008-07       Impact factor: 3.969

Review 4.  Monocyte and macrophage abnormalities in systemic lupus erythematosus.

Authors:  Yi Li; Pui Y Lee; Westley H Reeves
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-07-31       Impact factor: 4.291

Review 5.  Antibodies against C1q in patients with systemic lupus erythematosus.

Authors:  Marten Trendelenburg
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

6.  Anti-C1q antibodies are associated with systemic lupus erythematosus disease activity and lupus nephritis in northeast of China.

Authors:  Cai-Qin Zhang; Lei Ren; Fei Gao; Feng-Yun Mu; Yan-Qiu You; Yan-Hong Liu
Journal:  Clin Rheumatol       Date:  2011-02-23       Impact factor: 2.980

7.  Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.

Authors:  Heikki Julkunen; Susanne Ekblom-Kullberg; Aaro Miettinen
Journal:  Rheumatol Int       Date:  2011-06-26       Impact factor: 2.631

8.  Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis.

Authors:  Jing Wang; Yuan-Yuan Qi; Xue-Ping Chen; Li Ma; Li-Li Zhang; Yu Zhao; Mei Wang
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

9.  Anti-C1q autoantibodies in murine lupus nephritis.

Authors:  L A Trouw; M A Seelen; R Visseren; J M G J Duijs; H Benediktsson; E de Heer; A Roos; C van Kooten; M R Daha
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

10.  Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus.

Authors:  Olivier C Meyer; Pascale Nicaise-Roland; Nolwenn Cadoudal; Sabine Grootenboer-Mignot; Elisabeth Palazzo; Gilles Hayem; Philippe Dieudé; Sylvie Chollet-Martin
Journal:  Arthritis Res Ther       Date:  2009-06-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.